The University of Southampton
University of Southampton Institutional Repository

Tolvaptan use in severe neonatal autosomal dominant polycystic kidney disease (ADPKD): the pharmaceutical challenge

Tolvaptan use in severe neonatal autosomal dominant polycystic kidney disease (ADPKD): the pharmaceutical challenge
Tolvaptan use in severe neonatal autosomal dominant polycystic kidney disease (ADPKD): the pharmaceutical challenge
Unlicensed medications are used all the time in the management of diseases in childhood. Tolvaptan (Jinarc®) is a vasopressin V2-receptor antagonist licensed for use to slow the progression of cyst development and renal insufficiency of ADPKD in adults with CKD stage 1 to 3 with evidence of rapidly progressing disease. Studies of animal models implicate the antidiuretic hormone arginine vasopressin and its messenger cyclic adenosine monophosphate (cAMP) as promoters of kidney-cyst cell proliferation and luminal fluid secretion.
tolvaptan, polycystic kidney, adpkd, neonatal kidney
0003-9888
Olalekan, Kazeem
76a8cf63-1365-45b4-ad42-099d78e4bd85
Fox, Andy
39222d91-d4b5-42e8-b46b-4702340f0f9e
Gilbert, Rodney
2a1da00f-9bfc-4859-a473-41ca462019db
Olalekan, Kazeem
76a8cf63-1365-45b4-ad42-099d78e4bd85
Fox, Andy
39222d91-d4b5-42e8-b46b-4702340f0f9e
Gilbert, Rodney
2a1da00f-9bfc-4859-a473-41ca462019db

Olalekan, Kazeem, Fox, Andy and Gilbert, Rodney (2016) Tolvaptan use in severe neonatal autosomal dominant polycystic kidney disease (ADPKD): the pharmaceutical challenge. Archives of Disease in Childhood, 101 (e2). (doi:10.1136/archdischild-2016-311535.61).

Record type: Meeting abstract

Abstract

Unlicensed medications are used all the time in the management of diseases in childhood. Tolvaptan (Jinarc®) is a vasopressin V2-receptor antagonist licensed for use to slow the progression of cyst development and renal insufficiency of ADPKD in adults with CKD stage 1 to 3 with evidence of rapidly progressing disease. Studies of animal models implicate the antidiuretic hormone arginine vasopressin and its messenger cyclic adenosine monophosphate (cAMP) as promoters of kidney-cyst cell proliferation and luminal fluid secretion.

Full text not available from this repository.

More information

e-pub ahead of print date: 17 August 2016
Published date: 1 September 2016
Keywords: tolvaptan, polycystic kidney, adpkd, neonatal kidney

Identifiers

Local EPrints ID: 412978
URI: http://eprints.soton.ac.uk/id/eprint/412978
ISSN: 0003-9888
PURE UUID: 6a0f5a2f-2c50-4a5f-a6ef-686370ff1f9b
ORCID for Kazeem Olalekan: ORCID iD orcid.org/0000-0001-7666-7117

Catalogue record

Date deposited: 10 Aug 2017 16:30
Last modified: 20 Mar 2020 17:31

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×